Institutional ownership reaches 39% at European copper producer Aurubis AG, granting major influence and exposure to the firm's performance as shares surge over 120% in a year.
After years of losses, Evolent Health has broken into profitability with a rising capital base. While its Return on Capital Employed (ROCE) remains low, the accelerating trend suggests a potential inflection point for the healthcare services firm.
With major infrastructure projects complete, Hess Midstream pivots to a capital-light strategy, prioritizing cash returns and debt reduction. Chevron's indirect stake adds a new dimension to the company's financial priorities.
Pfizer's shares have staged a notable rebound in recent months, drawing investor attention as the company pivots towards oncology. We examine whether the current valuation reflects its long-term growth potential or lingering post-pandemic challenges.
Nike is consolidating its outdoor ambitions, merging its ACG and trail running lines into a dedicated performance brand. The strategic pivot targets a lucrative market as the sportswear giant seeks to reinvigorate growth against a backdrop of a multi-year stock decline.
Following its annual results showing $5 billion in revenue, Antero Resources (AR) faces a valuation conundrum as its share price weakens. While long-term returns remain stellar, recent momentum has cooled, raising questions about its fair value in a shifting energy landscape.
Biosimilars developer Alvotech (NASDAQ: ALVO) presents a complex picture for investors, with recent short-term share price gains starkly contrasted by a punishing 57% decline over the past year. As the stock trades at a significant discount to some analyst targets, the market debates whether this signals a prime opportunity or reflects deeper, unresolved challenges.
A series of class action lawsuits alleging misleading statements about the progress of Ramaco Resources' Brook Mine project has cast a shadow over the company's disclosure practices and market valuation, shifting investor focus from operational metrics to governance credibility.
As freezing temperatures grip the nation, federal regulators and consumer advocates are sounding the alarm on a predictable wave of scams. Fraudsters are exploiting the weather, posing as utility companies to pressure victims into immediate payments.
Elon Musk's artificial intelligence venture, xAI, is launching a major recruitment drive for cryptocurrency and traditional finance experts to train its AI models. This strategic push coincides with the company's impending $1 trillion merger with SpaceX, signaling a deeper integration of Musk's tech and financial ambitions.
Stani Kulechov, founder of the decentralized finance protocol Aave, has purchased a luxury five-story residence in London's Notting Hill for £22 million, reportedly below asking price, as crypto entrepreneurs increasingly invest in traditional real estate assets.
U.S.-listed spot Bitcoin ETFs snapped a 10-day outflow streak with their largest single-day haul in over two months, as major funds attracted fresh capital despite BTC's slide below key support levels.
Two Fraser restaurant employees have been arrested on felony assault charges after police say they pursued customers suspected of leaving without paying a $100 tab, with one allegedly brandishing a firearm and the other applying a chokehold.
CNBC's Jim Cramer has added Amgen to his watchlist, expressing strong confidence in the biotech giant's future following positive updates at the JPMorgan Healthcare Conference. He specifically highlighted the strength of the company's development pipeline.
CNBC's Jim Cramer suggests Chipotle Mexican Grill's stock, despite potential for a muted quarter, may be poised for a rebound given its depressed valuation, highlighting it in his weekly market game plan.
CNBC's Jim Cramer expresses apprehension ahead of Advanced Micro Devices' quarterly report, suggesting even strong results may not satisfy a market exhibiting a new, unforgiving pattern toward chip stocks.
CNBC's Jim Cramer has spotlighted Merck & Co. as a strategic holding, praising the pharmaceutical giant's acquisition-driven strategy to build a more balanced portfolio ahead of its blockbuster drug's patent cliff.
CNBC's Jim Cramer has placed PepsiCo on his radar, expressing specific concerns that the consumer giant's Frito-Lay snack division faces headwinds from the rising popularity of GLP-1 weight-loss drugs, even as the stock shows recent strength.
CNBC's Jim Cramer has placed Palantir Technologies on his radar ahead of its quarterly report, expressing confidence in the data analytics firm's performance and highlighting the combative leadership style of CEO Alex Karp.
As The Walt Disney Company prepares to report earnings, CNBC's Jim Cramer places the media giant under scrutiny, highlighting persistent challenges in its streaming business and theme park operations that investors will be watching closely.
